MannKind (MNKD) Competitors

Alkermes (NASDAQ:ALKS) and MannKind (NASDAQ:MNKD) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, community ranking, risk, valuation, dividends and media sentiment.

Does the MarketBeat Community prefer ALKS or MNKD?

Alkermes received 113 more outperform votes than MannKind when rated by MarketBeat users. Likewise, 70.41% of users gave Alkermes an outperform vote while only 60.41% of users gave MannKind an outperform vote.

Company	Underperform	Outperform
Alkermes	Outperform Votes 702 70.41%	Underperform Votes 295 29.59%
MannKind	Outperform Votes 589 60.41%	Underperform Votes 386 39.59%

Do insiders and institutionals hold more shares of ALKS or MNKD?

95.2% of Alkermes shares are held by institutional investors. Comparatively, 49.5% of MannKind shares are held by institutional investors. 4.9% of Alkermes shares are held by insiders. Comparatively, 3.0% of MannKind shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Is ALKS or MNKD more profitable?

Alkermes has a net margin of 23.57% compared to MannKind's net margin of 8.07%. Alkermes' return on equity of 30.80% beat MannKind's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	23.57%	30.80%	19.09%
MannKind	8.07%	-17.74%	8.68%

Which has more risk and volatility, ALKS or MNKD?

Alkermes has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500. Comparatively, MannKind has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500.

Do analysts rate ALKS or MNKD?

Alkermes presently has a consensus target price of $38.50, suggesting a potential upside of 37.80%. MannKind has a consensus target price of $9.56, suggesting a potential upside of 106.09%. Given MannKind's stronger consensus rating and higher possible upside, analysts plainly believe MannKind is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67
MannKind	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.22

Does the media prefer ALKS or MNKD?

In the previous week, Alkermes had 7 more articles in the media than MannKind. MarketBeat recorded 21 mentions for Alkermes and 14 mentions for MannKind. MannKind's average media sentiment score of 0.98 beat Alkermes' score of 0.92 indicating that MannKind is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MannKind	6 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger earnings and valuation, ALKS or MNKD?

Alkermes has higher revenue and earnings than MannKind. Alkermes is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.56B	2.96	$367.07M	$2.17	12.88
MannKind	$285.50M	4.94	-$11.94M	$0.10	46.40

Summary

Alkermes beats MannKind on 12 of the 19 factors compared between the two stocks.